SAN FRANCISCO and BOSTON — October 10, 2025 — Leads & Copy — Apogee Therapeutics, Inc. has announced the closing of its previously announced underwritten public offering, raising approximately $345 million before deductions.
The offering included 8,048,782 shares of common stock, incorporating the full exercise of the underwriters’ option to purchase 1,097,561 additional shares, priced at $41.00 per share. Additionally, pre-funded warrants to purchase 365,853 shares were offered at $40.99999 per warrant, each with an exercise price of $0.00001 per share, exercisable immediately.
Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen acted as joint book-running managers, with BTIG as passive bookrunner. The offering was made via a written prospectus, as part of an effective registration statement filed with the SEC on August 12, 2024. Copies of the final prospectus supplement are available on the SEC’s website and from the book-running managers.
Apogee Therapeutics is focused on advancing novel biologics for inflammatory and immunology markets, including treatments for Atopic Dermatitis, asthma, and other indications. Their lead program, APG777, is being developed for Atopic Dermatitis.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com
Source: Apogee Therapeutics
